NivolumabPsoriasis following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1717卷 / 1期

关键词：

D O I：

10.1007/s40278-018-51284-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：214 / 214

相关论文

共 50 条

[41] HydroxychloroquineEosinophilia following off-label use: case report
Reactions Weekly, 2021, 1867 (1) : 204 - 204
[42] DexamethasoneMucormycosis following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 181 - 181
[43] HydroxychloroquineHaemolysis following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 376 - 376
[44] IvabradinePhosphene following off-label use: case report
Reactions Weekly, 2019, 1769 (1) : 267 - 267
[45] CeftriaxoneCholelithiasis following off-label use: case report
Reactions Weekly, 2021, 1880 (1) : 118 - 118
[46] SpironolactoneDysmenorrhoea following off-label use : case report
Reactions Weekly, 2024, 2018 (1) : 430 - 430
[47] AmantadineConstipation following off-label use: case report
Reactions Weekly, 2019, 1760 (1) : 20 - 20
[48] MethylprednisoloneOsteoporosis following off-label use: case report
Reactions Weekly, 2025, 2053 (1) : 203 - 203
[49] OmalizumabFever following off-label use: case report
Reactions Weekly, 2019, 1773 (1) : 265 - 265
[50] DenosumabHypocalcaemia following off-label use: case report
Reactions Weekly, 2020, 1808 (1) : 108 - 108

← 1 2 3 4 5 →